[Local immunity indices during the chigain treatment of chronic cystitis in children]

Area of Science:

• Pediatric Nephrology
• Immunology
• Urology

Background:

• Chronic pyelonephritis (CP) in children can lead to significant renal damage.
• Attendant cystitis complicates CP treatment and may affect patient outcomes.
• Current treatment modalities for pediatric CP with cystitis require optimization.

Purpose of the Study:

• To evaluate the efficacy of chigain as an immune replacement therapy in children with chronic pyelonephritis and cystitis.
• To assess the impact of chigain on clinical, urinalysis, cystoscopy, and immunoglobulin levels.
• To determine the role of immunotherapy in the multimodal treatment of pediatric CP.

Main Methods:

• A cohort of 117 children (aged 4-14) with chronic pyelonephritis was studied.
• 57 children with concurrent cystitis received multimodal treatment including intravesical chigain instillations.
• Treatment efficacy was monitored via clinical assessment, urinalysis, cystoscopy, and measurement of urinary secretory immunoglobulins (SIg A1, SIg A2, IgG).

Main Results:

• Chigain demonstrated the ability to initiate clinical response in pediatric patients.
• Positive trends were observed in urinalysis and cystoscopy findings post-treatment.
• Significant improvements were noted in the levels of urinary secretory immunoglobulins, indicating immune modulation.

Conclusions:

• Chigain acts as an effective immune replacement therapy in the context of multimodal treatment.
• The findings support the inclusion of chigain in the therapeutic regimen for children suffering from chronic pyelonephritis with cystitis.
• Immunotherapy with chigain offers a promising approach to managing complex pediatric urinary tract infections.